Efficacy of eculizumab in a patient with immunoadsorption- dependent catastrophic antiphospholipid syndrome: A case report

Medicine (United States)

Volumn 93, Issue 26, 2014, Pages

  Kronbichler, Andreas ^a   Frank, Renate ^a   Kirschfink, Michael ^b   Szilágyi, Ágnes ^c   Csuka, Dorottya ^c   Prohászka, Zoltán ^c   Schratzberger, Peter ^a   Lhotta, Karl ^d   Mayer, Gert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d Academic Teaching Hospital Feldkirch   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; IMMUNOGLOBULIN; METHYLPREDNISOLONE; RITUXIMAB; STEROID; MONOCLONAL ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT INHIBITION; DEEP VEIN THROMBOSIS; DIALYSIS; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOADSORPTION; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; KIDNEY BIOPSY; LUNG HEMORRHAGE; LUNG INJURY; LUNG INSUFFICIENCY; PLASMAPHERESIS; REPEATED DRUG DOSE; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; COMPLICATION; IGA DEFICIENCY; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROCEDURES; TERMINAL DISEASE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIPHOSPHOLIPID SYNDROME; CATASTROPHIC ILLNESS; FEMALE; HUMANS; IGA DEFICIENCY; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84917728306     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000143     Document Type: Article

References (10)

1. Cervera R, Font J, Gomez-Puerta JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205-1209.
2. Gomez-Puerta JA, Sanin-Blair J, Galarza-Maldonado C. Pregnancy and catastrophic antiphospholipid syndrome. Clin Rev Allergy Immunol. 2009;36:85-90.
3. Salmon JE, Heuser C, Triebwasser M, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011;8:e1001013.
4. Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Med. 2013;11:95.
5. Shapira I, Andrade D, Allen SL, et al. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012;64:2719-2723.
6. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011;11:2523-2527.
7. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013;13:2179-2185.
8. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362:1744-1745.
9. Pierangeli SS, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibodymediated thrombophilia. Arthritis Rheum. 2005;52:2120-2124.
10. Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol. 2013;148:313-321.